Patient characteristics
| Patient no. . | Age/sex . | HLA . | GVHD . | |||
|---|---|---|---|---|---|---|
| A . | B . | DR . | DRB1* . | |||
| Group A | ||||||
| 1 | 37/M | 2, 11 | 39, 62 | 4, 8 | NT | + |
| 2 | 47/F | 24, 26 | 15, 61 | 4, 12 | NT | − |
| 3 | 48/M | NT | NT | 4, − | NT | + |
| 4 | 46/M | 24, 26 | 35, 54 | 4, 9 | NT | − |
| 5 | 51/M | 2, 24 | 51, 54 | 4, 11 | NT | + |
| 6 | 56/M | 2, 24 | 52, 56 | 12, 15 | 1201/1502 | + |
| 7 | 35/M | 11, 33 | 39, 44 | NT | NT | − |
| 8 | 44/M | 11, 24 | 54, 67 | 4, 15 | 0405/1502 | + |
| 9 | 41/F | 11, 24 | 51, 61 | 12, 15 | NT | + |
| 10 | 48/M | 11, 24 | 52, 56 | 4, 4 | 0405/0410 | − |
| Group B | ||||||
| 11 | 41/F | 2, 24 | 62, — | 4, 15 | 0401/1501 | − |
| 12 | 31/F | 2, 31 | 35, 44 | 3, 4 | 0301/0404 | − |
| 13 | 30/F | 3, 11 | 7, 8 | 3, 4 | 0301/0404 | − |
| 14 | 41/F | 2, 3 | 7, — | NT | NT | + |
| 15 | 46/F | 2, 29 | 40, 44 | 1, 4 | 0101/0404 | + |
| 16 | 41/F | 2, 28 | 7, 35 | 4, 15 | 0407/1501 | − |
| 17 | 51/F | 1, 2 | 7, 8 | 3, 15 | 0301/1501 | − |
| 18 | 43/F | 1, 2 | 39, 70 | 4, 13 | 0401/1301 | − |
| 19 | 50/F | 1, 32 | 8, 44 | 1, 3 | 0101/0301 | + |
| 20 | 42/F | 2, 11 | 17, 44 | 4, 7 | 0401/0701 | + |
| 21 | 49/F | 1, 31 | 8, 27 | 4, 13 | 0401/1301 | − |
| 22 | 53/F | 2, 29 | 44, 62 | 7, 14 | 0701/1401 | + |
| 23 | 47/F | 23, 31 | 35, 44 | 4, 15 | 0407/1503 | − |
| 24 | 54/F | 1, 2 | 8, 62 | 3, 13 | 0301/1301 | − |
| 25 | 49/F | 2, — | 39, 44 | 11, 15 | 1104/1501 | + |
| 26 | 39/F | 2, 3 | 7, 44 | 4, 13 | 0407/1301 | − |
| 27 | 43/F | 3, 25 | 18, 63 | 4, 13 | 0405/1301 | − |
| 28 | 59/F | 2, 32 | 44, 57 | 7, 13 | 0701/1301 | + |
| 29 | 52/F | 3, 9 | 7, 14 | 7, 15 | 0701/1501 | − |
| 30 | 48/F | 2, 26 | 18, 51 | 11, 15 | 1101/1502 | − |
| 31 | 59/F | 1, 24 | 7, 55 | 11, 15 | 1101/1501 | − |
| Patient no. . | Age/sex . | HLA . | GVHD . | |||
|---|---|---|---|---|---|---|
| A . | B . | DR . | DRB1* . | |||
| Group A | ||||||
| 1 | 37/M | 2, 11 | 39, 62 | 4, 8 | NT | + |
| 2 | 47/F | 24, 26 | 15, 61 | 4, 12 | NT | − |
| 3 | 48/M | NT | NT | 4, − | NT | + |
| 4 | 46/M | 24, 26 | 35, 54 | 4, 9 | NT | − |
| 5 | 51/M | 2, 24 | 51, 54 | 4, 11 | NT | + |
| 6 | 56/M | 2, 24 | 52, 56 | 12, 15 | 1201/1502 | + |
| 7 | 35/M | 11, 33 | 39, 44 | NT | NT | − |
| 8 | 44/M | 11, 24 | 54, 67 | 4, 15 | 0405/1502 | + |
| 9 | 41/F | 11, 24 | 51, 61 | 12, 15 | NT | + |
| 10 | 48/M | 11, 24 | 52, 56 | 4, 4 | 0405/0410 | − |
| Group B | ||||||
| 11 | 41/F | 2, 24 | 62, — | 4, 15 | 0401/1501 | − |
| 12 | 31/F | 2, 31 | 35, 44 | 3, 4 | 0301/0404 | − |
| 13 | 30/F | 3, 11 | 7, 8 | 3, 4 | 0301/0404 | − |
| 14 | 41/F | 2, 3 | 7, — | NT | NT | + |
| 15 | 46/F | 2, 29 | 40, 44 | 1, 4 | 0101/0404 | + |
| 16 | 41/F | 2, 28 | 7, 35 | 4, 15 | 0407/1501 | − |
| 17 | 51/F | 1, 2 | 7, 8 | 3, 15 | 0301/1501 | − |
| 18 | 43/F | 1, 2 | 39, 70 | 4, 13 | 0401/1301 | − |
| 19 | 50/F | 1, 32 | 8, 44 | 1, 3 | 0101/0301 | + |
| 20 | 42/F | 2, 11 | 17, 44 | 4, 7 | 0401/0701 | + |
| 21 | 49/F | 1, 31 | 8, 27 | 4, 13 | 0401/1301 | − |
| 22 | 53/F | 2, 29 | 44, 62 | 7, 14 | 0701/1401 | + |
| 23 | 47/F | 23, 31 | 35, 44 | 4, 15 | 0407/1503 | − |
| 24 | 54/F | 1, 2 | 8, 62 | 3, 13 | 0301/1301 | − |
| 25 | 49/F | 2, — | 39, 44 | 11, 15 | 1104/1501 | + |
| 26 | 39/F | 2, 3 | 7, 44 | 4, 13 | 0407/1301 | − |
| 27 | 43/F | 3, 25 | 18, 63 | 4, 13 | 0405/1301 | − |
| 28 | 59/F | 2, 32 | 44, 57 | 7, 13 | 0701/1301 | + |
| 29 | 52/F | 3, 9 | 7, 14 | 7, 15 | 0701/1501 | − |
| 30 | 48/F | 2, 26 | 18, 51 | 11, 15 | 1101/1502 | − |
| 31 | 59/F | 1, 24 | 7, 55 | 11, 15 | 1101/1501 | − |
Group A patients with non-Hodgkin lymphoma underwent autologous PBSCT; Group B patients with breast cancer underwent autologous BMT. A and B signify HLA class I loci, and the numbers in the table are the alleles detected. DR signifies an HLA class II locus.
M, male; F, female; NT, not tested; +, GVHD developed; −, GVHD did not develop.
Subgroup alleles detected by DNA typing.